ZIOPHARM Oncology, Inc. (ZIOPHARM), incorporated in September 2003, is a development-stage biopharmaceutical company. The Company focuses on developing and commercializing a portfolio of in-licensed cancer drugs that address unmet medical needs. The Company is focused on licensing and developing drug candidate families that are related to cancer therapeutics on the market or in development and that can be developed in intravenous (IV) and/or oral forms of administration. As of December 31, 2007, it was in Phase I and Phase I/II studies for two product candidates known as darinaparsin (ZIO-101), palifosfamide (ZIO-201) and indibulin (ZIO-301). (Source: 10KSB)
OncoGenex is a private biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company's three product candidates are designed to inhibit the production of specific proteins associated with treatment resistance and which are over-produced in response to a variety of cancer treatments. OGX-011 is completing evaluation in five Phase 2 clinical studies in prostate, lung, and breast cancers. Encouraging preliminary data from four of the Phase 2 studies has been reported in 2007. OGX 427 has begun evaluation in Phase 1 clinical studies, while our third product candidate, OGX-225, has completed preclinical pharmacology studies.
Helix BioPharma Corp. (Helix) is a Canada-based biopharmaceutical company developing products for the treatment of cancer and precancerous conditions. The Company has several projects in the development stage. Helix is developing Topical Interferon Alpha-2b for the treatment of early stage cervical dysplasia and ano-genital warts (AGW) caused by the Human Papilloma Virus (HPV). Helix’s Topical Interferon Alpha-2b formulation incorporates the Company’s Biphasix technology. During the fiscal year ended July 31, 2007 (fiscal 2007), the Company concluded its German Phase II clinical study of Topical Interferon Alpha-2b in women with precancerous, HPV induced low-grade cervical lesions (LSIL). DOS47 was conceived to offer cancer therapy by leveraging a natural process in the body called the urea cycle, to produce an anti-cancer effect. L-DOS47 is designed to target lung cancer cells in the body. (Source: ARS)
http://www.procyonbiopharma.com
Procyon Biopharma (Procyon) is a biotechnology company actively engaged in the development of innovative therapeutics in the fields of cancer and HIV/AIDS. The Company leverages its strengths in clinical research and development, bringing products through early- to mid-stage clinical trials and then evaluating the best options for further development, such as partnerships and licensing. Procyon's core products include PCK3145, a non-toxic peptide for advanced metastatic prostate cancer; TVT-Dox, a Tumor Vasculature Targeting technology for the treatment of solid tumors; and PPL-100, a protease inhibitor for drug-resistant HIV/AIDS. Headquartered in Montreal, Procyon shares are listed on the Toronto Stock Exchange (TSX) under the ticker symbol PBP.
Progen Pharmaceuticals Limited (Progen) is an Australia-based company. During the fiscal year ended June 30, 2008 (fiscal 2008), the principal activities of the Company were discovery, research and development of biopharmaceutical therapeutics for the treatment of human diseases, and the provision of contract services related to the process development, manufacture and assurance of biological products. The product platforms include Epigenetics, Angiogenesis and Cell Proliferation. On July 2, 2008, the Company spun-out its manufacturing business as a wholly owned subsidiary company, PharmaSynth Pty Ltd (PharmaSynth). PharmaSynth is focused on the provision of contract pharmaceutical manufacturing services. On July 23, 2008, the Company discontinued the PI-88 phase III study in liver cancer (the PATHWAY trial). In February 2008, the Company completed the acquisition of the United States-based biotechnology company CellGate, Inc.
ChemGenex Pharmaceuticals Limited (ChemGenex) is a genomics-driven pharmaceutical development company focused on improving the lives of patients by developing personalized therapeutics in the areas of cancer, obesity, diabetes and depression. It has two molecules in Phase II clinical trials in the United States and has a pipeline of pre-clinical anti-cancer compounds in development. These discoveries are then validated with a range of systems biology approaches and evaluated in terms of drugability. The target discovery and validation approach is based on a collection of tissue and deoxyribonucleic acid (DNA) samples from worldwide population groups; validated animal model systems for diabetes/obesity and depression/anxiety; a 1400 central processing unit parallel Linux cluster supercomputer for statistical analysis of genetic data, and the eXpress Technology Platform, a research engine for rapid target discovery and validation for any disease. (Source: 20-F)
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory